Click here to close now.




















Welcome!

News Feed Item

Cancer Biomarker Market (Global & USA) to 2018 - Trends and Pipeline Analysis

ReportsnReports.com offer Global & USA Cancer Biomarker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis) in its store.

DALLAS, Aug. 7, 2014 /PRNewswire-iReach/ -- Global & USA Cancer Biomarker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-development, Business Strategies, Industry Trends, and Pipeline Analysis) is a comprehensive report on the cancer biomarker industry and its impact on the health system. This report tackles the growing market interest in oncogenic biomarkers, personalized medicine, companion diagnostics and the associated market environment.

(Photo - http://photos.prnewswire.com/prnh/20140807/134312)  

Cancer biomarkers are molecular or genetic moieties (e.g., cells, proteins/peptides, genetic mutations, gene products, enzymes, or hormones) that not only are readily identifiable, but easily quantified in the lab setting. They function primarily to identify or correlate significantly with the severity or occurrence of a certain disease state. The rise in number of oncogenic biomarkers over the last number of years has massive potential in the healthcare industry and serves to propel both the personalized medicine and companion diagnostic markets.

One of the most import aspects of biomarkers is their use to diagnose and assess the progress of disease states in patients. As quantitative markers, these agents also offer the ability to monitor response to certain drug treatments and so are important in the area of personalized medicine.

Individualized, targeted or personalized medicine aims to increase the efficacy of therapeutics via genetic testing and companion diagnostics. Personalized therapeutics and associated companion diagnostics will be more specific and effective thereby giving pharma/biotech companies a significant advantage to recuperate R&D costs. Personalized medicine will reduce the frequency of adverse drug reactions and therefore have a dramatic impact on health economics. Developmental and diagnostic companies will benefit from lower discovery and commercialization costs and more specific market subtypes.

Purchase Report @ http://www.reportsnreports.com/purchase.aspx?name=291987.

This report describes the current technologies that are propelling the cancer biomarker and companion diagnostic market. It examines the current genetic diagnostic tests and companion diagnostic assays that are in use by the medical and pharmaceutical industry today. Current developments in personalized medicine and the pharmacogenomics revolution are discussed. The emerging trends that appear in the global market and the most developed market (US) are elucidated and analysed. This study reveals market figures of the overall biomarker market and the cancer biomarker space (2013-2018). Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry.

The study also provides a comprehensive financial, business strategy and product review of key players in the cancer biomarker industry. Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified.

In summary, the cancer biomarker and associated companion diagnostic market have huge opportunities for growth. This industry will revolutionize the healthcare system and will improve therapeutic effectiveness and reduce the severity of adverse effects. It has enormous potential for investment and the emergence of genetic-based in vitro diagnostics.

Table of Contents

1.0 Executive Summary 13

2.0 Global Burden of Cancer 20

3.0 Oncogenic Biomarkers – An Overview 54

4.0 Biomarker Validation 73
4.1 Introduction 73
4.2 Phases of Biomarker Validation 73
4.3 Biomarker Validation and Clinical Trials 75

5.0 Current and Prospective Oncogenic Biomarkers 77

6.0 Cancer Biomarker Test Market Analysis 2013-2018 101

7.0 Oncology Biomarker Market Main Industry Players 115
7.1 23andMe 115
7.2 Affymetrix 116
7.3 Ambry Genetics 118
7.4 Astex Pharmaceuticals 119
7.5 Atossa Genetics 121
7.6 CuraGen 122
7.7 Celera Corporation (Quest Diagnostics) 122
7.8 Celldex Therapeutics 122
7.9 deCode Genetics (Amgen) 124
7.10 Foundation Medicine 124
7.11 Illumina 125
7.12 Genelex 126
7.13 Genomic Health 126
7.14 Myriad 126
7.15 Nodality 127
7.16 OriGene Technologies 130
7.17 Randox 130
7.18 Qiagen 131

8.0 Oncology Biomarker Market Products and Kits 133
8.1 Oncology Companion Diagnostic Tests 133
8.2 23andMe 135
8.3 Affymetrix 139
8.4 Ambry Genetics 140
8.5 Astex Pharmaceuticals 150
8.6 Atossa Genetics 150
8.7 BioMerieux 151
8.8 Celera (Quest Diagnostics) 151
8.9 deCode Genetics 153
8.10 Foundation Medicine 155
8.11 Illumina 157
8.12 Genelex 160
8.13 Genomic Health 160
8.14 Myriad Genetics 163
8.15 Nodility 168
8.16 OriGene 168
8.17 Randox 172
8.18 Qiagen 173
8.19 Roche 177

Single User License of the Report is US $ 3335 for Discount Inquire @ http://www.reportsnreports.com/contacts/discount.aspx?name=291987.

9.0 Market Participant Financial and Business Strategy Analysis 178
9.1 23andMe 178
9.2 Affymetrix 180
9.3 Astex Pharmaceuticals (Otuska Pharamceutical) 189
9.4 Atossa Genetics 192
9.5 BioMerieux 195
9.6 Celera (Quest Diagnostics) 200
9.7 Celldex Therapeutics 206
9.8 deCode Genetics (Amgen) 207
9.9 Foundation Medicine 208
9.10 Illumina 210
9.11 Genelex 213
9.12 Genomic Health 213
9.13 Myriad 214
9.14 Nodality 218
9.15 Qiagen 220

10.0 Objective Business and Strategic Analysis of the Cancer Biomarker Market 225

List of Tables

List of Figures

Other Reports by Kelly Scientific:

Personalized Medicine and Companion Diagnostic Market - A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment - Highlights a number of significant pharmacos and gives details of their operations, products, financials and business strategy.

  • 23andMe
  • Affymetrix
  • Astex Pharmaceuticals
  • Atossa Genetics
  • CuraGen
  • Celera Corporation (Quest Diagnostics)
  • Celldex Therapeutics
  • deCode Genetics (Amgen)
  • Illumina
  • Genelex
  • Myriad
  • Nodality
  • Qiagen

Pharmaceutical Industry in China - Cutting-Edge Analysis of Multinational and Chinese Pharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges - Highlights a number of significant Chinese and multinational pharmacos and gives details of their operations, products, financials and business strategy.

  • Amoytop Biotech
  • Active Pharmaceutical Products
  • Beijing Continent Pharmaceuticals
  • FusoGen Pharmaceuticals
  • Shanghai Huaguan Biochip
  • SiBiono GeneTech
  • Abbott
  • AstraZeneca
  • Boehringer Ingelheim
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson & Johnson Medical
  • Merck
  • Novartis
  • Pfizer
  • Roche

About Us:

ReportsnReports.com is an online market research reports library of 350,000+ in-depth studies of over 5000 micro markets. Call +1 888 391 5441 with your research requirements or email the details on [email protected] This e-mail address is being protected from spambots. You need JavaScript enabled to view it and we would be happy to help you find the business intelligence that you need. Not limited to the biotechnology industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, consumer goods, environment, medical devices, healthcare, food and beverages, retail, water, advanced materials and much more.

Media Contact: Ritesh Tiwari, ReportsnReports.com, + 1 888 391 5441, [email protected]

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE ReportsnReports.com

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In a recent research, analyst firm IDC found that the average cost of a critical application failure is $500,000 to $1 million per hour and the average total cost of unplanned application downtime is $1.25 billion to $2.5 billion per year for Fortune 1000 companies. In addition to the findings on the cost of the downtime, the research also highlighted best practices for development, testing, application support, infrastructure, and operations teams.
SYS-CON Events announced today that HPM Networks will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. For 20 years, HPM Networks has been integrating technology solutions that solve complex business challenges. HPM Networks has designed solutions for both SMB and enterprise customers throughout the San Francisco Bay Area.
Learn how you can use the CoSN SEND II Decision Tree for Education Technology to make sure that your K–12 technology initiatives create a more engaging learning experience that empowers students, teachers, and administrators alike.
Container technology is sending shock waves through the world of cloud computing. Heralded as the 'next big thing,' containers provide software owners a consistent way to package their software and dependencies while infrastructure operators benefit from a standard way to deploy and run them. Containers present new challenges for tracking usage due to their dynamic nature. They can also be deployed to bare metal, virtual machines and various cloud platforms. How do software owners track the usag...
As Marc Andreessen says software is eating the world. Everything is rapidly moving toward being software-defined – from our phones and cars through our washing machines to the datacenter. However, there are larger challenges when implementing software defined on a larger scale - when building software defined infrastructure. In his session at 16th Cloud Expo, Boyan Ivanov, CEO of StorPool, provided some practical insights on what, how and why when implementing "software-defined" in the datacent...
As organizations shift towards IT-as-a-service models, the need for managing and protecting data residing across physical, virtual, and now cloud environments grows with it. CommVault can ensure protection and E-Discovery of your data – whether in a private cloud, a Service Provider delivered public cloud, or a hybrid cloud environment – across the heterogeneous enterprise. In his session at 17th Cloud Expo, Randy De Meno, Chief Technologist - Windows Products and Microsoft Partnerships at Com...
Mobile, social, Big Data, and cloud have fundamentally changed the way we live. “Anytime, anywhere” access to data and information is no longer a luxury; it’s a requirement, in both our personal and professional lives. For IT organizations, this means pressure has never been greater to deliver meaningful services to the business and customers.
SYS-CON Events announced today that VividCortex, the monitoring solution for the modern data system, will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. The database is the heart of most applications, but it’s also the part that’s hardest to scale, monitor, and optimize even as it’s growing 50% year over year. VividCortex is the first unified suite of database monitoring tools specifically desi...
The Software Defined Data Center (SDDC), which enables organizations to seamlessly run in a hybrid cloud model (public + private cloud), is here to stay. IDC estimates that the software-defined networking market will be valued at $3.7 billion by 2016. Security is a key component and benefit of the SDDC, and offers an opportunity to build security 'from the ground up' and weave it into the environment from day one. In his session at 16th Cloud Expo, Reuven Harrison, CTO and Co-Founder of Tufin,...
In their session at 17th Cloud Expo, Hal Schwartz, CEO of Secure Infrastructure & Services (SIAS), and Chuck Paolillo, CTO of Secure Infrastructure & Services (SIAS), provide a study of cloud adoption trends and the power and flexibility of IBM Power and Pureflex cloud solutions. In his role as CEO of Secure Infrastructure & Services (SIAS), Hal Schwartz provides leadership and direction for the company.
SYS-CON Events announced today that MobiDev, a software development company, will exhibit at the 17th International Cloud Expo®, which will take place November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. MobiDev is a software development company with representative offices in Atlanta (US), Sheffield (UK) and Würzburg (Germany); and development centers in Ukraine. Since 2009 it has grown from a small group of passionate engineers and business managers to a full-scale mobi...
There are many considerations when moving applications from on-premise to cloud. It is critical to understand the benefits and also challenges of this migration. A successful migration will result in lower Total Cost of Ownership, yet offer the same or higher level of robustness. In his session at 15th Cloud Expo, Michael Meiner, an Engineering Director at Oracle, Corporation, analyzed a range of cloud offerings (IaaS, PaaS, SaaS) and discussed the benefits/challenges of migrating to each offe...
"We've just seen a huge influx of new partners coming into our ecosystem, and partners building unique offerings on top of our API set," explained Seth Bostock, Chief Executive Officer at IndependenceIT, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
Digital Transformation is the ultimate goal of cloud computing and related initiatives. The phrase is certainly not a precise one, and as subject to hand-waving and distortion as any high-falutin' terminology in the world of information technology. Yet it is an excellent choice of words to describe what enterprise IT—and by extension, organizations in general—should be working to achieve. Digital Transformation means: handling all the data types being found and created in the organizat...
Chuck Piluso presented a study of cloud adoption trends and the power and flexibility of IBM Power and Pureflex cloud solutions. Prior to Secure Infrastructure and Services, Mr. Piluso founded North American Telecommunication Corporation, a facilities-based Competitive Local Exchange Carrier licensed by the Public Service Commission in 10 states, serving as the company's chairman and president from 1997 to 2000. Between 1990 and 1997, Mr. Piluso served as chairman & founder of International Te...